Sanofi - Regeneron Tout Additional Positive Data From Flagship Dupixent Product

  • Sanofi SA SNY and Regeneron Pharmaceuticals Inc REGN presented more positive data for their Dupixent product.
  • The companies said new Dupixent data showed a significant histological remission of eosinophilic esophagitis in children 1 to 11 years old. 
  • Eosinophilic esophagitis is a chronic inflammatory disease that damages the esophagus and prevents it from working properly.
  • In May 2022, FDA approved Dupixent 300 mg weekly for EoE in people aged 12 years and older, weighing at least 40 kg.
  • Related: Regeneron-Sanofi's Flagship Dupixent Becomes First FDA-Approved Treatment For Prurigo Nodularis.
  • 68% of patients on a higher dose and 58% on a lower dose achieved the primary endpoint of significant histological disease remission, compared to 3% for placebo. 
  • Children on the higher dose regimen also experienced significant improvements in abnormal endoscopic findings of their esophagus, with a reduction of 3.5 points compared to an increase of 0.3 points for the placebo. 
  • Symptomatically, a higher dose of Dupixent led to a numerical improvement in the days children experienced disease symptoms from baseline compared to placebo, though not statistically significant. 
  • Price Action: REGN stock closed at $730.92 on Monday, and SNY shares are up 0.84% at $39.43 during the premarket session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In:
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!